Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Xencor, Inc.
Deal Watch: BMS Returning IL-12 Candidate To Frequent Partner Dragonfly
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.
Deal Watch: AbbVie Leads J.P. Morgan Deal Rush, But BI, Genentech And Lilly Also Big Players
As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.
Finance Watch: Emalex Raises $250m To Fund Phase III Tourette’s Trial
Private Company Edition: The Paragon Biosciences-founded Emalex previously raised $35m when ecopipam was in Phase II. Also, Catalio Capital launches a “special situations” fund, Zenas raises $118m to develop a pipeline of autoimmune disease treatments and Lusaris emerges with $60m.
Deal With Gilead For Anti-CD123 Bispecific Offers Breath Of Fresh Air For MacroGenics
MacroGenics believes its next-gen anti-CD123 candidate MGD024 has a potentially favorable toxicity profile, as other bispecifics with the same target have floundered. But it lacks the cash to advance on its own.
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.